Business Wire

Takeda Expands Oncology Research, Demonstrating Commitment to Patient Community at 15th International Symposium on Myelodysplastic Syndromes

Share

Takeda Pharmaceutical Company Limited [TSE: 4502 / NYSE: TAK] today announced that it will present a total of five company-sponsored poster presentations, as well as an oral pipeline symposium, at the 15th International Symposium on Myelodysplastic Syndromes taking place in Copenhagen, Denmark from May 8-11, 2019. Takeda’s presentations will highlight the company’s investigations into the epidemiology, prognosis and patient reported outcomes for higher-risk myelodysplastic syndromes (HR-MDS) and the related conditions – chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) – to achieve a deep understanding of these rare cancers and the needs of this patient community.

“We are excited to join the MDS community at this upcoming meeting where we will share key findings around Takeda’s research in HR-MDS, CMML and AML,” said Hui Huang, PhD, Head, Oncology Global Outcomes Research at Takeda. “For over a decade, there has been little advancement in treatment options for people living with HR-MDS and CMML, despite poor patient outcomes. Takeda’s investment in this wide-ranging global outcomes research directly captures patient input to better understand these cancers, as well as AML, and the impact on their lives. These findings are an important aspect of our work as we strive to bring new treatment options to patients.”

At this year’s International Symposium on Myelodysplastic Syndromes, Takeda will present results from a variety of innovative research studies. These results are the first global systematic review of HR-MDS and CMML on incidence and prevalence, including the risk of transformation to AML. The results will also quantify the disease burden, discuss the difficulties associated with diagnosis and underscore the significant unmet need of this patient population. Some of this research was conducted in collaboration with the MDS Foundation – an international non-profit advocacy organization whose mission is to support and educate patients and healthcare providers with innovative research into the fields of MDS, AML and related myeloid neoplasms.

Five Takeda Oncology-sponsored abstracts were accepted for poster presentation, as well as an oral pipeline symposium during MDS 2019:

Note: All times listed are in Central European Standard Time

For more information, the MDS 2019 program is available here: https://mds.kenes.com/2019/scientific/scientific-program#.XJosUihKhdg

About Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

Myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) are rare forms of blood cancer that are caused by irregular blood cell production within the bone marrow. As a result of this irregular production, a person with MDS, CMML or AML does not have enough normal red blood cells, white blood cells and/or platelets in circulation. Symptoms for MDS, CMML and AML are often vague and related to low blood counts, and may include fatigue, shortness of breath, easy bruising or bleeding, loss of appetite, weakness, pale skin, fever and frequent or severe infections.

There are several classifications of MDS – lower risk to higher-risk – determined by blood counts, blast counts, mutations and cytogenetics. Higher-risk disease is defined as intermediate, high or very high risk on the International Prognostic Scoring System – Revised (IPSS-R), and these patients often have a poorer prognosis. In some cases, MDS and CMML can progress into AML.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

For more information, visit https://www.takeda.com

Contact information

Takeda Pharmaceutical Company Limited

Japanese Media
Kazumi Kobayashi
kazumi.kobayashi@takeda.com
+81 (0) 3-3278-2095

Media outside Japan
Victoria von Rinteln
victoria.vonrinteln@takeda.com
+1-617-444-4391

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data from the Phase 3 HELP Study Open-Label Extension Evaluate the Long-Term Safety and Efficacy of TAKHZYRO® (lanadelumab) in Reducing Hereditary Angioedema Attacks6.6.2020 10:05:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE). The analyses suggest that TAKHZYRO® (lanadelumab) is well-tolerated and can prevent hereditary angioedema (HAE) attacks over an extended treatment period, with sustained and consistent reduction in monthly attack rate across a range of different patient subgroups. The data are being presented at the 2020 European Academy of Allergy and Clinical Immunology (EAACI) Digital Congress. The original Phase 3 HELP Study was conducted in 125 patients aged 12 years and older over 26 weeks, making it the largest randomised, controlled prevention study in HAE, with the longest active treatment duration, to date.1 The HELP Study OLE was designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO for up to 2.5 years and was completed in Novemb

Next generation of DataOps, provided by Datalytyx, now available through Snowflake Partner Connect Program!5.6.2020 12:10:00 EESTPress release

Datalytyx today announced an expanded partnership with Snowflake, the Cloud Data Platform, that enables the next generation Datalytyx DataOps for Snowflake platform to be deployed for a 2 week trial on Snowflake. Customers can orchestrate the ingestion of data from many on-premise and cloud platforms via 3rd party data tools, model data easily, automatically test those models as part of their pipelines, launch AI/ML models and enable the consumption of data to deliver immediate stakeholder value. As a great example, in the midst of the Coronavirus pandemic, BOC, the UK market-leading gas supply company for delivery of healthcare oxygen, has faced unprecedented demand, from equipping Nightingale hospitals to delivering O2 cylinders in homes. Datalytyx have deployed their DataOps for Snowflake platform to help BOC manage their cylinder stock and logistics data, for all types of gases, to increase production efficiency and provide best-in-class customer service. “Datalytyx said they could

Pegasus Development AG: Green Light for Multiple Production Sites Worldwide5.6.2020 10:27:00 EESTPress release

Announcement: Expansion of the Pegastril-Nuevo production facility Under the leadership of board member Roberto Spano, the management of Pegasus Development AG has decided to further expand Pegastril-Nuevo production facilities. New production facilities will be set up at several locations across the world and the site in Turkey is being expanded. These investments will also create new jobs. The takeover and expansion of the following production facilities are planned in all 20 countries of Latin America, as well as France, Spain, Portugal, Greece, Cyprus, Nigeria, Ethiopia, Uganda, Tanzania, Mozambique, Angola, Mauritius, Guinea-Bissau, Cape Verde, São Tome, and Mongolia. The demand for disinfectants has skyrocketed as a result of the coronavirus. Especially high revenues are expected from products which are based on vegetable surfactants and are alcohol-free, such as Nuevo. This was the decisive factor in the management's decision to further expand the quantity and range of Nuevo pro

IDEMIA and BBVA Partner to Launch Spain’s First Payment Card Made of Recycled PVC5.6.2020 10:00:00 EESTPress release

IDEMIA, the global leader in Augmented Identity, is supplying the very first cards made out of recycled plastics in Spain to BBVA. The bank will first distribute the cards to their Spanish customers with a BBVA Youth Account in June 2020. This new payment card is a strong commitment from BBVA to contributing to the United Nations Sustainable Development Goals for the fight against climate change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005037/en/ (Graphic: Business Wire) Each year, approximately 6 billion plastic payment cards are produced according to the 2018 Nilson Report1. In the context of the United Nations Sustainable Development Goals and the Paris Agreement, IDEMIA’s cutting-edge technology has been selected by BBVA, one of the largest banks in Spain, to migrate part of its existing first-use PVC cards to innovative recycled PVC cards. By the end of the year BBVA will enable more than half a million Spa

In COVID-19, Pudu Robotics Provides Non-contact Delivery Service in Hundreds of Hospitals Worldwide5.6.2020 10:00:00 EESTPress release

During COVID-19, hundreds of Pudu Robotics’ robot Pudubot is offering delivery service in hospitals worldwide. This non-contact delivery service by Pudubot helps avoid the spread of virus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200605005095/en/ (Photo: Business Wire) After the outbreak of COVID-19, the pandemic with the characteristic of human-to-human transmission, a large number of hospitals and restaurants are seeking help from Pudu Robotics out of an urgent need for non-contact delivery. Pudu Robotics responded positively by devoting robots to several hospitals in Seoul, South Korea, Beijing, China, Wuhan, China and so on. Because Pudu Robotics’ robots are fully automatic, they can achieve the delivery process all by themselves, which reduces contact between people and effectively prevents the spread of the virus. Pudubot is equipped with multi-sensor and positioning and navigation technology. With large-capacity

EIT Digital: Strengthening European Digital Infrastructure and Data Sovereignty5.6.2020 07:00:00 EESTPress release

Recent discussions around access to 5G technology and COVID-19 contact tracing apps highlight the need for European digital sovereignty. In its latest policy perspective report on ‘European Digital Infrastructure- and Data Sovereignty’, EIT Digital offers a concrete scenario-based framework for digital policy development. The study provides an overview of policy motivations, trends, instruments, and the roles of various actors in defining the perception of and perspectives for Europe’s digital sovereignty. “What becomes clear is that we need coordinated action between the policy shapers at European and national levels and the makers from business and industry to create a sovereign European digital reality. Key are policies that enhance innovation and respect European values and rights while creating equal economic opportunity for all actors,” says EIT Digital CEO Willem Jonker. EIT Digital collaborated with the Digital Enlightenment Forum to execute the report. The study supports the d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom